Navigation Links
Biopure Completes U.K. Regulatory Agency Inspection
Date:3/19/2008

CAMBRIDGE, Mass., March 19 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has completed its inspection of the company's Pennsylvania manufacturing facility. The inspection report contained no "Critical" and no "Major" deficiencies in compliance with good manufacturing practices. The MHRA report identified shortcomings characterized as "Other," with a request for a response detailing the company's corrective actions within 35 working days.

According to John Tomera, Director of Regulatory Affairs at Biopure, "We are pleased with the MHRA's inspection result, which attests to our efforts toward consistently maintaining quality standards. We anticipate being able readily to address all of the issues that were cited by the MHRA."

As previously announced, Biopure has pending with the MHRA a marketing authorization application to market Hemopure in the United Kingdom for acute anemia during elective orthopedic surgery where red blood cell transfusion is not available. The inspection is a routine part of the application procedure.

No inspection of the company's manufacturing facility in Massachusetts is scheduled at this time or expected to occur before the MHRA next communicates about the pending application.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer -- 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The company is developing Hemopure for other indications and is supporting the U.S. Navy's government- funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer -- 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since 1998.

Contact: Tiana Gorham

Biopure Corporation

(617) 234-6826

IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biopure Announces 2008 First Quarter Financial Results
2. Biopure Launches Updated Website
3. Biopure Announces Pricing of Equity Offering
4. Biopure Gives Update on Malaysia Joint Venture Discussions
5. Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing
6. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
7. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
8. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
9. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
10. Plurality Completes R&D of its HAL-256 Multicore Processor
11. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017   Sienna Biopharmaceuticals, Inc. , a ... announced that Richard Peterson will join the ... Peterson, who brings more than two decades of ... who is retiring at the end of April but ... Peterson joins Sienna from Novan, Inc., where he served ...
(Date:3/23/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Global Market for Bioproducts Should ... at a CAGR of 8.9%, This research ... into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs ...
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
Breaking Biology News(10 mins):